XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Fair Value of Options

The fair value of the stock options granted were estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:

						Three Months Ended March 31,
						2024						2023
Expected stock price volatility						57.2		%				59.3		%
Risk free interest rate						4.0		%				3.9		%
Expected life of options (years)						5.6						5.5
Expected annual dividend per share						$	—					$	—

Schedule of Stock Options Activity

A summary of the Company's stock options for the three months ended March 31, 2024 were as follows:

						Number of Shares						Weighted Average Exercise  Price						Weighted Average Remaining Years						Aggregate Intrinsic Value
						(in thousands)																		(in millions)
Options outstanding, December 31, 2023						23,002						$	11.69
Granted						4,033						$	14.23
Exercised						(439)						$	7.86
Forfeited						(271)						$	12.56
Expired						(20)						$	17.28
Options outstanding, March 31, 2024						26,305						$	12.13					6.4						$	23.9
Vested and unvested expected to vest, March 31, 2024						24,409						$	12.08					6.2						$	23.5
Exercisable at March 31, 2024						15,979						$	11.60					4.9						$	22.3

Schedule of Non-Vested RSU Activity under the Plan

A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2024 is as follows:

						Number of Shares						Weighted Average Grant Date Fair Value						Weighted  Average Remaining  Years						Aggregate Intrinsic Value
						(in thousands)																		(in millions)
Non-vested units as of December 31, 2023						10,033						$	13.37
Granted						3,251						$	15.35
Vested						(3,332)						$	13.49
Forfeited						(393)						$	14.66
Non-vested units as of March 31, 2024						9,559						$	13.92					2.5						$	112.6

Schedule of Equity Compensation Expenses

The following table summarizes information related to compensation expense recognized in the Company's Consolidated Statements of Operations related to the equity awards:

						Three Months Ended March 31,
(in thousands)						2024						2023
Research and development expense						$	4,871					$	8,490
Selling, general, and administrative expense						25,932						26,404
Total equity compensation expense						$	30,803					$	34,894

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (f)(2)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration